Published in Nat Rev Cancer on February 19, 2010
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study. Osteoporos Int (2012) 3.13
Resolvins and protectins in inflammation resolution. Chem Rev (2011) 3.09
Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med (2011) 2.39
Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab (2014) 2.35
Distinct ATOH1 and Neurog3 requirements define tuft cells as a new secretory cell type in the intestinal epithelium. J Cell Biol (2011) 2.21
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell (2015) 2.10
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res (2011) 2.06
Cytokine patterns differ seasonally between women with and without uterine leiomyomata. Am J Reprod Immunol (2013) 1.99
Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature (2015) 1.94
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest (2011) 1.87
Live imaging of tumor initiation in zebrafish larvae reveals a trophic role for leukocyte-derived PGE₂. Curr Biol (2012) 1.80
Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov (2012) 1.71
Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab (2012) 1.68
Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res (2013) 1.65
RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation. EMBO Mol Med (2014) 1.62
Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech (2013) 1.55
Dietary intake of PUFAs and colorectal polyp risk. Am J Clin Nutr (2012) 1.51
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo. J Thorac Cardiovasc Surg (2012) 1.49
Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med (2012) 1.47
A systematic review and meta-analysis of the ability of analgesic drugs to reduce metastasis in experimental cancer models. Pain (2015) 1.45
What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol (2012) 1.42
Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc Natl Acad Sci U S A (2013) 1.38
Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev (2010) 1.36
Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic Biol Med (2014) 1.34
Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat (2011) 1.31
Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene (2011) 1.29
Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab (2012) 1.28
Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res (2013) 1.24
Reconstruction of genome-scale metabolic models for 126 human tissues using mCADRE. BMC Syst Biol (2012) 1.24
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev (2011) 1.21
COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins Other Lipid Mediat (2011) 1.20
The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol (2012) 1.20
High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS One (2013) 1.19
EET signaling in cancer. Cancer Metastasis Rev (2011) 1.18
Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res (Phila) (2013) 1.17
Lipid metabolic reprogramming in cancer cells. Oncogenesis (2016) 1.16
Cox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis. Carcinogenesis (2010) 1.14
The immune system and inflammation in breast cancer. Mol Cell Endocrinol (2013) 1.12
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. Am J Pathol (2011) 1.12
PGE2 promotes angiogenesis through EP4 and PKA Cγ pathway. Blood (2011) 1.10
Phospholipase signalling networks in cancer. Nat Rev Cancer (2012) 1.10
Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol (2012) 1.09
Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol (2013) 1.09
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proc Natl Acad Sci U S A (2014) 1.09
Network-based pipeline for analyzing MS data: an application toward liver cancer. J Proteome Res (2011) 1.07
Mast cell chemotaxis - chemoattractants and signaling pathways. Front Immunol (2012) 1.07
Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol Rev (2013) 1.05
Gamma-tocotrienol induces apoptosis and autophagy in prostate cancer cells by increasing intracellular dihydrosphingosine and dihydroceramide. Int J Cancer (2011) 1.05
Polyunsaturated fatty acid metabolism in prostate cancer. Cancer Metastasis Rev (2011) 1.04
Is human cytomegalovirus a target in cancer therapy? Oncotarget (2011) 1.04
Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Rev (2011) 1.04
Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Res (2013) 1.04
Biomarkers for personalizing omega-3 fatty acid dosing. Cancer Prev Res (Phila) (2014) 1.02
Linoleic acid metabolite drives severe asthma by causing airway epithelial injury. Sci Rep (2013) 1.02
ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res (2011) 1.02
The diverse role of the PPARγ coactivator 1 family of transcriptional coactivators in cancer. Semin Cell Dev Biol (2012) 1.02
Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology (2015) 1.01
Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prev Res (Phila) (2013) 1.01
An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J (2013) 1.01
Prostaglandins antagonistically control Bax activation during apoptosis. Cell Death Differ (2010) 1.01
Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2. Breast Cancer Res Treat (2011) 1.00
Peroxisome proliferator-activated receptor δ promotes colonic inflammation and tumor growth. Proc Natl Acad Sci U S A (2014) 1.00
A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis. Carcinogenesis (2014) 0.99
Dietary fats and health: dietary recommendations in the context of scientific evidence. Adv Nutr (2013) 0.99
Current evidence linking polyunsaturated Fatty acids with cancer risk and progression. Front Oncol (2013) 0.98
Urinary PGE-M: a promising cancer biomarker. Cancer Prev Res (Phila) (2013) 0.97
Hypoxia-inducible factor-2α is essential in activating the COX2/mPGES-1/PGE2 signaling axis in colon cancer. Carcinogenesis (2012) 0.97
Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits adhesion of human endometriotic epithelial and stromal cells through suppression of integrin-mediated mechanisms. Biol Reprod (2013) 0.97
The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg). Curr Med Chem (2011) 0.97
Bioactive lipoxygenase metabolites stimulation of NADPH oxidases and reactive oxygen species. Mol Cells (2011) 0.97
Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med (2014) 0.97
Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer (2015) 0.96
Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. Prog Lipid Res (2013) 0.96
Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. Carcinogenesis (2011) 0.96
Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res (2013) 0.95
Prostaglandin E2 regulates liver versus pancreas cell-fate decisions and endodermal outgrowth. Dev Cell (2014) 0.95
The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer (2016) 0.95
ω-3 polyunsaturated fatty acids-derived lipid metabolites on angiogenesis, inflammation and cancer. Prostaglandins Other Lipid Mediat (2014) 0.95
The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget (2012) 0.94
Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases and cancer. J Clin Invest (2011) 0.93
miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol Cancer Res (2014) 0.93
Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. Cell Res (2015) 0.93
Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. PLoS One (2012) 0.93
Low molecular weight hyaluronan activates cytosolic phospholipase A2α and eicosanoid production in monocytes and macrophages. J Biol Chem (2013) 0.93
Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer Metastasis Rev (2014) 0.92
COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations. Cancer Causes Control (2013) 0.92
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma. Mol Cancer Ther (2012) 0.92
Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA. Proc Natl Acad Sci U S A (2015) 0.92
A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res (2013) 0.92
Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin Cancer Res (2012) 0.92
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst (2014) 0.91
Constructing a fish metabolic network model. Genome Biol (2010) 0.91
Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis. Anticancer Agents Med Chem (2013) 0.90
Associations between obesity and cancer: the role of fatty acid synthase. J Natl Cancer Inst (2012) 0.90
Aberrant PGE₂ metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. Int Immunopharmacol (2011) 0.90
ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma. Front Oncol (2012) 0.90
MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther (2012) 0.90
Cysteinyl leukotrienes and their receptors: bridging inflammation and colorectal cancer. World J Gastroenterol (2014) 0.90
The role of PGE2-associated inflammatory responses in gastric cancer development. Semin Immunopathol (2012) 0.90
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Cyclooxygenase in biology and disease. FASEB J (1998) 7.17
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science (2005) 5.68
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol (2009) 5.05
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res (2007) 4.69
Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell (2009) 4.69
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A (2006) 4.51
Coxibs and cardiovascular disease. N Engl J Med (2004) 4.42
Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood (2000) 4.34
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79
Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res (2007) 3.49
Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med (2002) 3.47
The cancer epigenome--components and functional correlates. Genes Dev (2006) 3.40
Altered eicosanoid levels in human colon cancer. J Lab Clin Med (1993) 3.32
Regulation of the immune response by prostaglandins. J Clin Immunol (1983) 3.12
Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med (2001) 2.98
Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med (2009) 2.68
Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem (2003) 2.65
The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett (2008) 2.64
Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J Immunol (1993) 2.63
Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood (2002) 2.61
Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell (2004) 2.60
15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem (2004) 2.55
Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol (2005) 2.48
Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med (2009) 2.41
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.41
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30
Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A (2003) 2.23
Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res (1998) 2.11
Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol (2000) 2.11
The role of leukotrienes in inflammation. Ann Intern Med (1994) 2.06
Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology (2009) 2.05
Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res (2002) 2.02
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev (2008) 2.00
Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A (2006) 1.97
Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood (2008) 1.91
The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23-->IL-17 axis. J Immunol (2007) 1.87
Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A (2006) 1.84
15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res (2006) 1.82
Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection. J Exp Med (2001) 1.79
Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res (2005) 1.74
Attenuated zymosan-induced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J Biol Chem (2001) 1.72
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) (2008) 1.71
Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med (2003) 1.69
Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res (2005) 1.68
Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis (2003) 1.66
Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res (1999) 1.65
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A (2009) 1.65
Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J Natl Cancer Inst (2003) 1.63
Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head Neck (2007) 1.58
Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev (2007) 1.57
The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med (2009) 1.56
Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res (2008) 1.54
The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis (2000) 1.53
Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res (2003) 1.53
Neoplasms escape selective COX-2 inhibition in an animal model of breast cancer. Ir J Med Sci (2009) 1.50
Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. Gastroenterology (2006) 1.47
Retracted Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol (2006) 1.46
Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. J Biol Chem (2001) 1.44
Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest (2003) 1.42
Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev (2006) 1.42
Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res (1999) 1.40
Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med (2000) 1.38
EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene (2006) 1.37
Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res (2004) 1.37
The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res (2005) 1.33
Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res (2002) 1.32
Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation. FASEB J (2006) 1.31
Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res (2008) 1.31
Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood (2003) 1.29
Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res (2006) 1.28
[6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res (2009) 1.26
Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol (2004) 1.25
Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci (2007) 1.24
Regulation of dendritic cell migration and adaptive immune response by leukotriene B4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood (2006) 1.23
15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res (2009) 1.23
Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis (2005) 1.22
Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res (2002) 1.22
Dietary fat and carcinogenesis. Mutat Res (1999) 1.21
A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res (2005) 1.20
Transcellular biosynthesis of cysteinyl leukotrienes in vivo during mouse peritoneal inflammation. Proc Natl Acad Sci U S A (2009) 1.20
5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol (2002) 1.19
Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology (2003) 1.17
Prostaglandin E2 promotes integrin alpha Vbeta 3-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. J Biol Chem (2002) 1.17
Cyclooxygenase-2-derived prostaglandin e2 protects mouse embryonic stem cells from apoptosis. Stem Cells (2007) 1.17
LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways. Biochem Biophys Res Commun (2005) 1.16
Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol (2006) 1.16
Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol (2007) 1.14
Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res (1988) 1.13
Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res (2004) 1.13
Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. J Immunol (2004) 1.13
Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem (2008) 1.12
PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun (2001) 1.11
Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res (2008) 1.10
Leukotriene B(4) stimulates Rac-ERK cascade to generate reactive oxygen species that mediates chemotaxis. J Biol Chem (2001) 1.10
CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell (2013) 1.71
COX-2 inhibition and colorectal cancer. Semin Oncol (2004) 1.53
Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proc Natl Acad Sci U S A (2005) 1.38
Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology (2005) 1.37
Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol (2004) 1.25
APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest (2011) 1.23
The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron (2010) 1.23
Cyclooxygenase-2-mediated DNA damage. J Biol Chem (2005) 1.18
The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol (2009) 1.16
Cyclooxygenase-1 signaling is required for vascular tube formation during development. Dev Biol (2005) 1.15
Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol (2012) 1.09
Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res (2012) 1.08
Bmp signaling is required for intestinal growth and morphogenesis. Dev Dyn (2006) 1.07
Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. Cancer Res (2010) 1.04
Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res (2007) 1.00
Controversy: PPARgamma as a target for treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol (2002) 0.97
Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases and cancer. J Clin Invest (2011) 0.93
The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer. Cancers (Basel) (2011) 0.92
Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor. Pancreas (2013) 0.91
Associations between obesity and cancer: the role of fatty acid synthase. J Natl Cancer Inst (2012) 0.90
Peroxisome proliferator-activated receptors and progression of colorectal cancer. PPAR Res (2008) 0.88
Role of inflammation and inflammatory mediators in colorectal cancer. Trans Am Clin Climatol Assoc (2014) 0.85
Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer (2012) 0.84
Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. Mol Cancer (2006) 0.80
Effects of transforming growth factor-alpha (TGF-alpha) in vitro and in vivo on reovirus replication. DNA Cell Biol (2004) 0.78
The Jeremiah Metzger Lecture: Inflammation, Immune Modulators, and Chronic Disease. Trans Am Clin Climatol Assoc (2015) 0.78
PPARγ agonists target aromatase via both PGE2 and BRCA1. Cancer Prev Res (Phila) (2012) 0.76
Ras up-regulation of cyclooxygenase-2. Methods Enzymol (2006) 0.75
Will an aspirin a day keep the endoscope away? Gastroenterology (2003) 0.75
The evolution of modern academic medicine continues. Gastroenterology (2002) 0.75
Disease prevention: the future is here. Gastroenterology (2004) 0.75
MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism. Dig Dis Sci (2007) 0.75
The physician-scientist in gastroenterology. Gastroenterology (2003) 0.75